T. Pieber Et Al. , "Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.," The lancet. Diabetes & endocrinology , vol.7, pp.528-539, 2019
Pieber, T. Et Al. 2019. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.. The lancet. Diabetes & endocrinology , vol.7 , 528-539.
Pieber, T., Bode, B., Mertens, A., Cho, Y., Christiansen, E., Hertz, C., ... Wallenstein, S.(2019). Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.. The lancet. Diabetes & endocrinology , vol.7, 528-539.
Pieber, TR Et Al. "Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.," The lancet. Diabetes & endocrinology , vol.7, 528-539, 2019
Pieber, TR Et Al. "Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.." The lancet. Diabetes & endocrinology , vol.7, pp.528-539, 2019
Pieber, T. Et Al. (2019) . "Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.." The lancet. Diabetes & endocrinology , vol.7, pp.528-539.
@article{article, author={TR Pieber Et Al. }, title={Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.}, journal={The lancet. Diabetes & endocrinology}, year=2019, pages={528-539} }